Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Free by publisher |
as soon as is submitted to ZB.
SURMOUNTing body weight barriers in type 2 diabetes.
Med. 4, 849-851 (2023)
The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.1.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Editorial
Keywords
Obesity
ISSN (print) / ISBN
2666-6359
e-ISSN
2666-6340
Journal
Med (N Y)
Quellenangaben
Volume: 4,
Issue: 12,
Pages: 849-851
Publisher
Cell Press
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)
Grants
German Center for Diabetes Research (DZD e.V.)
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted